Executives mingled with North Carolina leaders in the city of Wilson to ceremonially break ground on Johnson & Johnson’s ...

Johnson & Johnson said it is increasing U.S investments to more than $55 billion over the next four years, boosting spending ...

Johnson & Johnson (NYSE:JNJ) on Friday announced plans to boost its U.S. investments to more than $55B over the next four ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...

Employees filing pioneering suits against companies like JPMorgan Chase & Co. and Johnson & Johnson over prescription drug ...

Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor ...

Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American ...

The investment will be used to improve R&D infrastructure to develop new treatments and implement new technologies to improve ...

Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...

According to an announcement by the pharmaceutical company, Johnson & Johnson (JNJ) will invest over $55 billion in various ...

Johnson & Johnson MedTech announced today that the FDA cleared its Monarch Quest technology for robotic-assisted bronchoscopy ...